The global market for breast cancer diagnostic and drug technologies was about $20.8 billion in 2012. This market reached about $22.3 billion in 2014 and is expected to reach $27 billion in 2019, registering a compound annual growth rate (CAGR) of 4% through 2014-2019.
This report provides an update and overview on predictive testing in breast cancer diagnostics and drug technologies and global markets as well as global incidence rates for breast cancer. The study's objective is to review tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2014 to 2019. The comprehensive review includes global markets for current drugs, new developments, predictive diagnostic tests and new technologies, drugs and developments. The report forecasts market trends forecast trends for the use of current tests for better diagnosis and prognosis of breast cancer through 2019.
Important current diagnostic tests, technologies and developments; market share by drug, test and current products on the market; market share by company or product; and statistical information for types of breast cancer incidence and prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing, which provides vital information about the cancer.These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes information on current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, new developments and patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report
Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance development. This includes more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.
Browse more Cancer Market Research Reports